Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Neurocrine Biosciences in ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target hoisted by equities researchers at UBS Group from $162.00 to $176.00 in a research note issued to investors on ...

Visa and Abbott are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...